aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
0.3124
+0.0047 (1.53%)
Sep 30, 2026, 1:50 PM EDT - Market open
aTyr Pharma Employees
As of December 31, 2025, aTyr Pharma had 60 total employees, including 58 full-time and 2 part-time employees. The number of employees increased by 1 or 1.69% compared to the previous year.
Employees
60
Change (1Y)
1
Growth (1Y)
1.69%
Revenue / Employee
$3,167
Profits / Employee
-$1,013,450
Market Cap
30.64M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 60 | 1 | 1.69% | 58 | 2 |
| Dec 31, 2024 | 59 | 0 | - | 56 | 3 |
| Dec 31, 2023 | 59 | -11 | -15.71% | 56 | 3 |
| Dec 31, 2022 | 70 | 17 | 32.08% | 65 | 5 |
| Dec 31, 2021 | 53 | 10 | 23.26% | 49 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| IGC Pharma | 70 |
| Evaxion | 46 |
| Quince Therapeutics | 38 |
| Kyntra Bio | 34 |
| LeonaBio | 19 |
| Quantum BioPharma | 17 |
| Context Therapeutics | 15 |
ATYR News
- 1 day ago - Two stock picks from a money manager who expects small caps to roar in 2027 - Market Watch
- 6 days ago - Why is aTyr Pharma Stock (ATYR) Down 7% Today? - TipRanks
- 6 days ago - aTyr Pharma announces alignment with FDA on Phase 3 study of efzofitimod - TheFly
- 6 days ago - aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis - GlobeNewsWire
- 19 days ago - aTyr Pharma Proxy statement: Proxy filing - Filings
- 4 weeks ago - aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis - GlobeNewsWire
- 4 weeks ago - aTyr Pharma Proxy statement: Proxy filing - Filings
- 5 weeks ago - Ethos to Present at the Goldman Sachs Communacopia + Technology Conference - GlobeNewsWire